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index (ABI) 0.9, being an independent predictor of cardiovascular morbidity and mortality, it
is rarely used in the primary care. Various definitions for PAD (i.e., ABI 0.9 or ABI 0.95) exist.
In addition, a modified ABI (ABImod) using the lowest ankle pressure improves identification of
patients at risk. The prevalence of PAD in primary care and association of different ABI calcula-
tions with atherosclerotic disease burden is not known.
Design: The researchwasconductedas aprospective cross-sectional study. Finnishhealthcentres
and 99 general practitioners were selected and trained for ABI measurement. Consecutive
patients were recruited using inclusion criteria: age 50e69 years and one or more cardiovascular
risk factors or age 70 years or calf pain during exercise. A total of 817 patients were recruited.
Methods: Research methods included interview and Doppler measurement of brachial and ankle
pressures.
Results: An ABImod 0.9 yielded the highest prevalence of PAD (47.7%), had the best sensitivity
and identified the highest number of patientswith coronary artery disease (CAD), cerebrovascular
disease (CVD), PAD, CAD/CVD/PAD and polyvascular disease (PVD) at the cost of reduced speci-
ficity. All ABI calculations were independently associated with atherosclerotic disease burden.
Interestingly, ABI 1.4 had the strongest association with CVD.XIII Annual Meeting 3e6 September, 2009, European Society for Vascular Surgery, Oslo, Norway.
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tion detects more number of patients at risk at the cost of reduced specificity. The association
of high ABI with CVD noted in this study warrants future research for validation.
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Lower extremity peripheral arterial disease (PAD) is
common in the general population and is associated with
two- to fivefold increased risk of future cardiovascular
morbidity and mortality.1e3 It is recognised as a coronary
heart disease risk equivalent4 and its prevalence is pre-
dicted to increase parallel to ageing of the population.5,6
However, both the public and primary-care physicians are
poorly aware of these risks.7,8 Moreover, PAD detection and
treatment in the general population is infrequent compared
with that of coronary artery disease (CAD) and cerebro-
vascular disease (CVD). Most importantly, typical signs and
symptoms of PAD are infrequent,5,9,10 making it difficult to
detect this condition by clinical examination alone.11,12
Ankleebrachial index (ABI) measurement has been
proven to be reliable when performed by vascular experts,
family physicians and nurses.13 The association of low-ABI
(i.e., 0.9) with high cardiovascular co-morbidity has been
demonstrated to reflect polyvascular disease and athero-
thrombosis as well as to predict future cardiovascular
events and mortality.1e3,9,14e16 In addition, it has been
demonstrated to have excellent reliability as well as good
sensitivity and specificity.12,17e20
Although ABI 0.9 is generally accepted as the optimal
cut-off value, it underestimates the prevalence of PAD in the
elderly21 and, therefore, other cut-off values have also been
suggested, such as ABI 0.95.22 Calculating ABI as the ratio
of the higher of the two systolic ankle pressures divided by
the systolic brachial pressure results in underestimation of
the risk for cardiovascular events; this issue can be resolved
by using the lower of the ankle pressures.23e25 Interestingly,
abnormally high ABI values are also related to future
cardiovascular morbidity and mortality.26,27 Therefore,
there is a need to correlate these different ABI calculations
with cardiovascular disease burden to allow more accurate
risk stratification. In fact, ABI has been demonstrated to
improve the accuracy of cardiovascular risk prediction
beyond the Framingham risk score.28
We hypothesised that the prevalence of PAD in patients
presenting to Finnish primary care is higher than anticipated
and that use of different ABI calculations (i.e., ABI 0.9,
ABI 0.95 andmodified ABI 0.9) and ABI 1.4would result
in improved detection of patients at risk, that is, improved
correlation with the atherosclerotic disease burden.
Materials and methods
Study population and data collection
Approximately a third of all Finnish health centres were
recruited for the study on the basis of uniform geographical
distribution. General practitioners (nZ 99) were trained
hands-on by vascular surgeons (NO, JV, ES and MV) for ABImeasurement and collection of study data. The researchers
were advised to collect data of 10 consecutive study subjects
fulfilling the inclusion criteria for measurement of ABI,
modified from the Trans-Atlantic Inter-Society Consensus for
the Management of PAD (TASC II).20 The following inclusion
criteria were considered in this study: (1) 50e69 years of age
and one or more cardiovascular risk factors (e.g., smoking,
hypertension, diabetes or dyslipidaemia); (2) age 70 years or
more; or (3) claudication defined as pain in the calf during
exercise. Smoking habits were graded as never or current/
former smoker. Exclusion criteria were specified as immobile
or permanently institutionalised patients. Each participant
provided voluntary informed consent. A total of 817 patients
were recruited. The medical history was based on interview
and previous medical records. CVD was defined as previous
transient ischaemic attack (TIA), ischaemic stroke, carotid
endarterectomy, percutaneous transluminal angioplasty
(PTA) or stenting in the carotid region. CAD was defined as
previously documented disease, coronary artery by-pass
grafting (CABG) or PTA in the coronary arteries. PAD was
defined as documented clinical symptomatic PAD, peripheral
arterial vascular procedure (e.g., by-pass, endarterectomy,
PTA or amputation). Polyvascular disease (PVD) was defined
as documented atherosclerosis in at least two arterial beds.
The study sites were trained to store the data on an Internet-
based data-collection portal (Digium Enterprises Ltd.
Finland). Data collection was carried out between May 2008
and March 2009. The study was approved by the Ethical
Committee of the Helsinki University Hospital.ABI measurement
All the study sites used similar Doppler ultrasonic devices
(Nicolet, USA). Standardised measurement of both brachial
systolic pressures and ankle pressures from anterior tibial
artery and posterior tibial artery of both lower limbs
following 15 min of rest was performed according to the
recommendations of the American Heart Association.29 The
pressure values were documented in an Internet-based data-
collection portal (Digium Enterprises Ltd. Finland). After
data collection, the following parameters were calculated:
(1) ABI, that is, the ratio of the higher of the two systolic
ankle pressures (posterior and anterior tibial arteries) to the
higher of the right and left brachial artery pressures. In case
of a discrepancy of 10 mmHgormore in blood pressure values
between the twoupper arms, thehigher brachial readingwas
used. ABI was calculated for both limbs and the lower of the
two values was used. Two cut-off values, 0.9 and 0.95
were used as the defining criteria of PAD or abnormal ABI. 2)
ABImod was calculated using the lower of the two systolic
ankle pressuremeasurements. The cut-off value of0.9 was
used as the definition of PAD or abnormal ABI. (3) ABI 1.4
was used as the definition of incompressible vessels or
abnormally high ABI.
Table 1 Prevalence of documented peripheral arterial
disease (PAD) and abnormal ankleebrachial index values
(ABI) in the three recruitment subgroups.
Variable Age 50e69þ
risk factor
(nZ 378)
Age 70 years
(nZ 439)
Calf pain
(nZ 151)
PAD (%) 6.3 10.3 23.8
ABI 0.9 (%) 12.1 23.2 35.8
ABI 0.95 (%) 23.7 37.7 41.7
ABIlmod 0.9 (%) 39.5 53.1 55.6
ABI 1.4 (%) 5.9 9.0 9.9
Modified Ankleebrachial Index 229Sample-size consideration and statistical analysis
A two-sided 95% confidence interval (CI) was determined
for estimating the prevalence of PAD. According to the
previous data, the prevalence of PAD was estimated as
6.9e30%.8e10,22,30e32 Inclusion of 750 patients would
result in a 95% CI of 17.3e23.0% (if the mean prevalence
was 20%) and 95% CI of 26.8e33.4% (if the mean preva-
lence was 30%). SPSS version 14.0 (SPSS Inc., Chicago, IL,
USA) was used to analyse the data. To estimate the true
prevalence of PAD, those with previously documented
history of PAD were defined as PAD positive independent
of their measured ABI. Binary logistic regression analysis
adjusted for potential confounders (e.g., age, sex, dia-
betes, dyslipidaemia, hypertension and smoking habits)
was used to study the independent association among
different ABI definitions (i.e., ABI 0.9, ABI 0.95,
ABImod 0.9 and ABI 1.4) with cardiovascular disease
burden (e.g., CAD, CVD, PAD, CAD/CVD/PAD or PVD). The
sensitivity, specificity and positive predictive value (PPV)
and negative predictive value (NPV) were determined for
the different ABI calculations. Statistical significance was
set at p< 0.05.Table 2 Patient characteristics.
Variable All patients ABI 0.9 (23.0%) ABIlmod
(nZ 817) (nZ 188) p (nZ 379
Age 70.4 (9.5) 74.2 (9.4) 0.000 72.6 (9.
Male sex (%) 418 (51.2) 92 (48.9) 0.472 188 (49
Calf pain (%) 151 (18.5) 54 (28.7) 0.000 84 (22
Smoking (%) 340 (41.6) 91 (48.4) 0.028 166 (43
Current (%) 105 (12.9) 33 (17.6) 57 (15
Former (%) 235 (28.8) 58 (30.9) 109 (28
Diabetes (%) 316 (38.7) 78 (41.5) 0.382 154 (40
Hypertension (%) 613 (75.0) 151 (80.3) 0.052 301 (79
Dyslipidaemia (%) 558 (68.3) 135 (71.8) 0.219 261 (68
CAD (%) 211 (25.8) 74 (39.4) 0.000 119 (31
CVD (%) 91 (11.1) 34 (18.1) 0.000 57 (15
PAD (%) 70 (8.5) 48 (25.5) 0.000 59 (15
CAD/CVD/PAD (%) 286 (35.0) 108 (57.4) 0.000 170 (44
PVD (%) 73 (8.9) 39 (20.7) 0.000 54 (14
Continuous variables: Student’s t-test for independent samples. Dich
Coronary artery disease (CAD), cerebrovascular disease (CVD) and p
defined as documented atherosclerosis in 2 arterial beds. Smoking:Results
Patient characteristics
Prevalence of documented PAD was highest in those
patients recruited to the study on the basis of pain in the
calf during exercise, and the prevalence of ABImod 0.9
was the highest in all the three study groups (Table 1).
Prevalence of ABImod 0.9 was the highest (46.4%) while
that of ABI 0.9 was the lowest (23.0%) and that of
ABI 0.95 was an intermediate between these two (31.0%)
(Table 2). The true prevalence of PAD (documented history
of PADþ ABI criteria) was as follows: ABImod 0.9 (47.7%),
ABI 0.9 (25.7%) and ABI 0.95 (33.3%).
The patients with abnormal ABI were significantly older
than those with normal ABI values (Table 2). Patients with
ABI 1.4 (Table 2) were predominantly male. Calf pain
during exercise was more frequent in all low-ABI categories
(0.9, 0.95 and ABImod 0.9) compared with the normal
ABI category (Table 2). Smoking was more frequent among
patients with ABI 0.9 (pZ 0.028) and ABI 0.95
(pZ 0.045) than among those with normal ABI (Table 2).
Diabetes was more frequent among those with ABI 1.4
(pZ 0.022) (Table 2). CAD, CVD, CAD/CVD/PAD or PVD
were more frequent in all abnormal ABI categories (Table
2). Documented PAD was more frequent in all low-ABI
categories (Table 2).
Diagnostic accuracy of different ABI calculations in
the detection of atherosclerotic disease burden
ABImod 0.9 identified the highest number of patients with
documented CAD (119/211 patients; 56.4%), CVD (57/91
patients; 62.6%), PAD (59/70 patients; 84.3%), CAD/CVD/
PAD (170/286 patients; 59.4%) and PVD (54/73 patients;
74.0%) (Table 2). ABImod 0.9 had the highest sensitivity
and NPVs for the detection of all disease modalities at the0.9 (46.4%) ABI 0.95 (31.0%) ABI 1.4 (7.5%)
) p (nZ 253) p (nZ 61) p
7) 0.000 73.5 (9.5) 0.000 73.4 (9.7) 0.011
.6) 0.384 124 (49.0) 0.394 44 (72.1) 0.001
.2) 0.016 63 (24.9) 0.002 15 (24.6) 0.215
.8) 0.209 118 (46.6) 0.045 23 (37.7) 0.534
.0) 43 (17.0) 1 (1.6)
.8) 75 (29.6) 22 (36.1)
.6) 0.306 97 (38.3) 0.867 32 (52.5) 0.022
.4) 0.006 202 (79.8) 0.030 40 (65.6) 0.079
.9) 0.681 176 (69.6) 0.560 42 (68.9) 0.902
.4) 0.001 91 (36.0) 0.000 24 (39.3) 0.013
.0) 0.001 43 (17.0) 0.000 13 (21.3) 0.007
.6) 0.000 51 (20.2) 0.000 9 (14.8) 0.070
.9) 0.000 133 (52.6) 0.000 33 (54.1) 0.001
.2) 0.000 44 (17.4) 0.000 11 (18.0) 0.009
otomous variables: Chi-square test. Ankleebrachial index (ABI).
eripheral arterial disease (PAD). Polyvascular disease (PVD) was
current or former smoker.
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230 N.K.J. Oksala et al.cost of reduced specificity (Table 3). The corresponding
values for ABI 0.95 were intermediate between ABI 0.9
and ABImod 0.9 (Table 3).
Association of different ABI modalities with the
atherosclerotic disease burden
ABI 0.9 and ABI 0.95 were significantly and indepen-
dently associated with all cardiovascular disease manifes-
tations (Table 4). ABImod 0.9 and ABI 1.4 showed no
independent association with CAD while they were inde-
pendently and significantly associated with all other
cardiovascular disease manifestations (Table 4).
Interestingly, according to the risk ratios, an ABI 0.9
had the strongest association with CAD, PAD, CAD/CVD/PAD
and PVD while ABI 1.4 had the strongest association with
CVD (Table 4).
Discussion
The trueprevalence of PADbasedonABI and thedocumented
history of PAD in Finnish primary-care centres ranged from
25.7% to 47.7%, which is high. The ABImod detected the
highest number of patients at risk, that is, with the heaviest
atherosclerotic disease burden at the cost of reduced spec-
ificity. All the ABI calculations showed an independent
association with the atherosclerotic disease burden, espe-
cially with PVD. The novel, independent and strong associa-
tion of elevated ABI (1.4) with CVDwarrants future studies.
Currently, guidelines recommend risk factor modification
and antithrombotic medication to decrease the risk of
cardiovascular diseases in all patients with PAD, including
asymptomatic patients, based on ABI measurement with
a cut-off value of 0.9 measured from higher ankle pressure
value.20 However, our study clearly shows that patients with
ABI 0.9 measured from the lower ankle pressure (LAP)
value have increased risk for cardiovascular diseases as well,
and, following the traditional recommendation, a high
proportion of patients remain without adequate treatment.
PAD has been shown to correlate with the risk for
atherothrombotic manifestations in coronary arteries and
cerebrovascular circulation. Previous studies on the reli-
ability of ABI methods and threshold in detecting PAD
support our findings. Niazi et al. compared the sensitivity
and specificity of a modified ABI with a threshold value of
ABI 0.9 calculated from the LAP with the current method
(higher ankle pressure (HAP)) using digital subtraction
angiography (DSA) as the gold standard in 107 patients and
208 limbs.25 A threshold value of ABI 0.9 was used. The
sensitivity of the HAP and LAP ABI for the diagnosis of PAD
was 0.69 and 0.84, respectively, and specificity 0.83 and
0.64, respectively.25 These values are in accordance with
the results of the present study. Schro¨der et al. investi-
gated the association of ABI calculated from HAP and LAP
with the atherosclerotic lesions in lower extremity exam-
ined with ultrasound.24 Similarly, the modified LAP ABI was
a superior method of calculating ABI to identify PAD.24
Sensitivity of ABI measured from HAP and LAP was 0.68 and
0.89, respectively, and specificity 0.99 and 0.93, respec-
tively.24 These findings of increased sensitivity of LAP ABI
are in agreement with the results discussed earlier.In
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Modified Ankleebrachial Index 231study, Guo et al.33 studied the threshold value of ABI in
diagnosing PAD and the relationship between the ABI value
and stenosis in the arteries of the lower extremity. DSA was
used as the gold standard for defining arterial lesions and
HAP was used when calculating ABI. They concluded that
the cut-off value of 0.95 was the threshold value for
detecting PAD in the study population with 0.91 sensitivity
and 0.86 specificity.33 In the present study, an ABI 0.95
remained as an intermediate between ABI 0.9 and
ABImod 0.9 in all disease modalities with respect to
sensitivity and specificity.
We consider the present selected primary-care cohort
comparable with the previous studies with obvious excep-
tions. The prevalence of co-morbidities in the present
cohort is slightly different compared with those in the
previous studies e diabetes, hypertension and dyslipidae-
mia were more frequent in the present cohort than in the
Diehm’s GetABI study recruiting primary-care subjects 65
years of age.9 The prevalence of co-morbidities in the
present study are in line with those recorded in the PAD
Awareness, Risk, and Treatment: New Resources for
Survival (PARTNERS) study with similar inclusion criteria.8
Prevalence of CAD (25.8% vs. 19.2%), CVD (11.1% vs. 8.9%)
and clinical PAD (8.5% vs. 8.7%) are well in line with the
GetABI study.9 Our cohort is representative of a high-risk
population since these co-morbidities were also more
frequent than in the population comprising the Rotter-
dam,10 Limburg32 and Minnesota31 studies. The prevalence
of current smokers (12.9%) was roughly the same as in the
GetABI,9 Minnesota,31 and less than half of the prevalence
reported in the Rotterdam10 or in the Limburg32 studies. We
consider that the differences in co-morbidities are a result
of different inclusion criteria and possible geographical and
socioeconomic differences in these studies and our cohort
is representative of patients with high risk of future
cardiovascular events.
Our finding of true PAD prevalence of 25.7%, according
to ABI 0.9 criteria and documented history of PAD, is in
agreement with the GetABI study,9 and slightly lower than
that of the PARTNERS study (29%) with similar inclusion
criteria as in the present study.8 Similar PAD prevalence was
detected in population studies such as the Minnesota study
with a cut-off value of <0.85 (26.5%)31 and with that of the
Rotterdam study,10 but higher than that in the Limburg
study (6.9%)32 and the Cardiovascular Health Study
(13.4%).22 In the Cardiovascular Health Study, the ABI cut-
off was <0.95 and the subjects were 65 years of age.22 As
the prevalence of PAD is highly dependent on population
age and ABI cut-off values, we consider these differences
are accountable for the different cut-off values and inclu-
sion criteria. The independent and strong association of
elevated ABI with CVD is supported by the previous studies,
in which it was associated with future cardiovascular
events.26,27 The independent association of different ABI
calculations with PVD is supported by the previous study in
which ABI 0.9 was shown to be associated with ultra-
sonographically detected atherosclerotic plaques in the
femoral and the carotid region.16
Our finding of increased true prevalence of PAD (47.7%
vs. 25.7%) using modified ABI calculation, taking into
account the lower of the two systolic ankle pressures, is
supported by results from a previous study in which there
232 N.K.J. Oksala et al.was a similar phenomenon (34.5% vs. 18.0%), although the
inclusion criteria were different.34 In line with our obser-
vation, in the detection of history of cardiac events,
ABImod 0.9 had increased sensitivity (46.1) at the cost of
reduced specificity (67.1).34 The sensitivity in the present
study was higher while specificity was of the same
magnitude.34
In the current study, the diagnosis of CAD, CVD and
symptomatic PAD was based on interview and previous
medical history, that is, on the clinically significant disease.
However, it is likely that there are undefined number of
patients with asymptomatic CAD and CVD and the true
prevalence would have been significantly higher. This, in
turn, would probably have increased the specificity of ABI in
the detection of atherothrombotic manifestations. To
increase the accuracy of the study in that respect, radio-
logical examination of coronary arteries and carotid arteries
would beneeded, although thiswas impossible to carry out in
this kindof study.However, thepresent studyencourages the
implementation of ABI measurement into primary care since
the NPVs obtained in the present study are high.
In primary care, PAD is highly prevalent in patients 70
years and older, 50 years and older with one cardiovascular
risk factor or in patients who have calf pain while walking.
ABImod calculation detects increased number of patients at
risk at the cost of reduced specificity. Current recommen-
dations to use cardiovascular risk prevention in patients
who have ABI 0.9 measured from higher ankle pressure
underestimated significantly the true number of patients at
increased risk. Our results demonstrate that the traditional
ABI calculation is more appropriate in the assessment of the
severity of PAD. The association of high ABI with CVD
warrants future research for validation of these results.
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